Log in

Relevant bibliographies by topics / COVID-19 – complications

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'COVID-19 – complications'

Author: Grafiati

Published: 16 November 2024

Last updated: 12 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'COVID-19 – complications.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "COVID-19 – complications"

1

H Jagtap Priya, Abhishek. "Post-Acute COVID-19 Complications." International Journal of Science and Research (IJSR) 12, no. 6 (2023): 863–65. http://dx.doi.org/10.21275/sr23413205037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

De Michele, Manuela, Joshua Kahan, Irene Berto, et al. "Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination." Circulation Research 130, no. 8 (2022): 1187–203. http://dx.doi.org/10.1161/circresaha.122.319954.

Full text

Abstract:

The risk of stroke and cerebrovascular disease complicating infection with SARS-CoV-2 has been extensively reported since the onset of the pandemic. The striking efforts of many scientists in cooperation with regulators and governments worldwide have rapidly brought the development of a large landscape of vaccines against SARS-CoV-2. The novel DNA and mRNA vaccines have offered great flexibility in terms of antigen production and led to an unprecedented rapidity in effective and safe vaccine production. However, as mass vaccination has progressed, rare but catastrophic cases of thrombosis have occurred in association with thrombocytopenia and antibodies against PF4 (platelet factor 4). This catastrophic syndrome has been named vaccine-induced immune thrombotic thrombocytopenia. Rarely, ischemic stroke can be the symptom onset of vaccine-induced immune thrombotic thrombocytopenia or can complicate the course of the disease. In this review, we provide an overview of stroke and cerebrovascular disease as a complication of the SARS-CoV-2 infection and outline the main clinical and radiological characteristics of cerebrovascular complications of vaccinations, with a focus on vaccine-induced immune thrombotic thrombocytopenia. Based on the available data from the literature and from our experience, we propose a therapeutic protocol to manage this challenging condition. Finally, we highlight the overlapping pathophysiologic mechanisms of SARS-CoV-2 infection and vaccination leading to thrombosis.

APA, Harvard, Vancouver, ISO, and other styles

3

Prasanthi, K. "Post COVID 19 Vaccination Associated Neurological Complications." International Journal of Science and Research (IJSR) 12, no. 7 (2023): 2136–40. http://dx.doi.org/10.21275/mr23727093509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kim, Geun-Jeon, and Young-Hoon Joo. "Laryngeal Complications of the COVID-19." Journal of The Korean Society of Laryngology, Phoniatrics and Logopedics 33, no. 3 (2022): 156–59. http://dx.doi.org/10.22469/jkslp.2022.33.3.156.

Full text

Abstract:

The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus-2 has upended the world of otolaryngology. After COVID-19 infection, patients experience various complication of symptoms due to injury of the larynx and lung/ respiratory system. Regardless of the patient’s severity, patients can experience several complications including dysphonia, vocal cord paralysis/paresis and sensory neuropathy. An emerging role for otolaryngologists in the coming weeks and months is the management of laryngeal complications of COVID-19. This review is intended to describe laryngeal complications in patients recovering from COVID-19 infection.

APA, Harvard, Vancouver, ISO, and other styles

5

Pařízek, Petr. "Cardiovascular complications and covid-19 infection." Intervenční a akutní kardiologie 20, no. 2 (2021): 78–80. http://dx.doi.org/10.36290/kar.2021.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Billah, Syed Muhammad Baqui, Jannatul Ferdous, A. K. M. Akbar Kabir, Farzana Ferdous Munmun, Indrani Kar, and Sabrina Tymee. "Post-COVID-19 Complications and Associated Factors among COVID-19 Survivors in Southern Part of Bangladesh." European Journal of Medical and Health Sciences 6, no. 5 (2024): 49–52. http://dx.doi.org/10.24018/ejmed.2024.6.5.2170.

Full text

Abstract:

Objective: SARS-CoV-2 infection causes numerous post-COVID (COV) complications among patients after recovery. Materials and Methods: This cross-sectional study was conducted at Sher-E-Bangla Medical College (SBMC), Barishal, Bangladesh, on 773 SARS-CoV-2 survivors from February to June 2021. Baseline characteristics, including comorbidity and post-COVID complications, were assessed. Results: The prevalence of post-COV complications was 22.8% (95% CI: 19.9%–25.9%). Fatigue (18.2%) was the most common complication, followed by shortness of breath (14.6%), cough (11.1%), chest pain (6.5%) and body ache (5.4%). Bronchial asthma (OR = 2.38), diabetes mellitus (OR = 2.07), Business and service (OR = 1.82), Good education (OR = 2.91), and tobacco use (OR = 1.40) were among the significant factors associated with the post-COV complications while hypertension and residence could not produce significant odds of association, though they were associated in the preliminary analysis. Conclusion: COVID-19 is associated with many complications involving all systems of the body. Certain comorbidities and demographic factors are associated with post-COV complications. The factors should be addressed in advance if the infection emerges again in the future.

APA, Harvard, Vancouver, ISO, and other styles

7

Hasan, Sameer Ibrahim, Imad A. Thanoon, Abdul-rahman I. A-J Thanoon, Omar SI Hasan, and Rwqaya S. Dawood. "Complications after Covid-19 vaccination." Annals of the College of Medicine, Mosul 44, no. 1 (2022): 88–94. http://dx.doi.org/10.33899/mmed.2022.134076.1151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Baysal-Kirac, Leyla, and Hilmi Uysal. "COVID-19 associate neurological complications." Neurological Sciences and Neurophysiology 37, no. 1 (2020): 1. http://dx.doi.org/10.4103/nsn.nsn_28_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Venkataramana, NK. "Cerebrovascular complications of COVID-19." Journal of Cerebrovascular Sciences 8, no. 1 (2020): 2. http://dx.doi.org/10.4103/jcvs.jcvs_13_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Rahkmonova, Sanobar, Jurabek Khaytboyev, Nargiza Zargarova, Dilfuza Otajonova, and Khabibulla Kazakov. "Kidney complications after COVID-19." International journal of health sciences 5, no. 3 (2021): 393–402. http://dx.doi.org/10.53730/ijhs.v5n3.1698.

Full text

Abstract:

This article discusses renal complications after Covid-19. It has now become clear that infection with the SARS-Cov-2 virus, which causes COVID-19, is almost identical - and this tells scientists which organs are most at risk. Specifically, the respiratory tract, intestines and, most likely, the kidneys, since it is there that both proteins necessary for the virus are present. Even the Ebola virus, found in the eye fluid of ex-patient’s months after recovery, causes blindness in 40 percent of those infected later. Therefore, given that SARS-CoV-2 is more likely to damage the lungs, doctors have speculated that the virus may cause irreversible changes in the respiratory system.

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "COVID-19 – complications"

1

De, Montigny Catherine. "Identification des sous-groupes d'individus les plus à risque de mortalité chez les cas confirmés de la COVID-19 au Québec." Master's thesis, Université Laval, 2021. http://hdl.handle.net/20.500.11794/68416.

Full text

Abstract:

En mars 2020, l’Organisation mondiale de la santé (OMS) déclarait la pandémie de la nouvelle maladie à coronavirus-19, aussi connue sous le nom de COVID-19. Le 26 juillet 2020, le SRAS-CoV-2 avait infecté 15 785 641 personnes, causant 640 016 décès. Un groupe de travail de l’Institut national de santé publique du Québec a été mandaté pour identifier les sous-groupes de la population vulnérables aux complications sévères liées à la COVID-19. L’objectif principal de ce mémoire est d’identifier les sous-groupes d’individus les plus à risque de mortalité chez les cas confirmés de la COVID-19 au Québec. Une étude de cohorte populationnelle de l’ensemble des cas confirmés de la COVID-19 au Québec a été réalisée. Parmi les 58 733 cas confirmés entre le 23 février 2020 et le 26 juillet 2020, 92% ont pu être jumelés avec les données du Système intégré de surveillance des maladies chroniques du Québec. La majorité de ces cas avait entre 20 et 64 ans, 60% étaient des femmes et 55% présentaient au moins une maladie chronique. Parmi les cas, 10% sont décédés, 12% ont été hospitalisés et 2% ont été admis aux soins intensifs. Peu de décès ont été observés avant l’âge de 60 ans. Les analyses de régression ont révélé que les sous-groupes d’individus les plus à risque de mortalité étaient les personnes âgées de 70 ans et plus, particulièrement de sexe masculin; les personnes aux prises avec certaines comorbidités; de même que les personnes plus jeunes cumulant des maladies chroniques. Ces résultats permettront aux décideurs du réseau de la santé de mettre en place des mesures dans le but de protéger les individus les plus vulnérables aux complications sévères liées à la COVID-19 et de prioriser des sous-groupes d’individus pour lesquels la vaccination serait le plus bénéfique.

APA, Harvard, Vancouver, ISO, and other styles

2

Rouzé, Anahita. "Impact de l'infection par SARS-CoV-2 sur l'épidémiologie des infections respiratoires bactériennes et des aspergilloses pulmonaires invasives chez les patients de réanimation sous ventilation mécanique." Electronic Thesis or Diss., Université de Lille (2022-....), 2024. https://pepite-depot.univ-lille.fr/ToutIDP/EDBSL/2024/2024ULILS017.pdf.

Full text

Abstract:

Objectifs : Le projet CoVAPid visait à étudier l'impact de l'infection par SARS-CoV-2 sur l'épidémiologie des infections respiratoires bactériennes et fongiques chez les patients de réanimation sous ventilation mécanique (VM). Trois entités ont été analysées : les infections pulmonaires bactériennes précoces, les infections respiratoires bactériennes acquises sous VM (IAVM) - pneumonies (PAVM) et trachéobronchites (TAVM) - et les aspergilloses pulmonaires invasives (API). Les objectifs principaux étaient de comparer la prévalence d'infection pulmonaire bactérienne précoce entre les patients admis pour COVID-19 et pour grippe, de comparer l'incidence d'IAVM chez les patients admis pour COVID-19, grippe ou un autre motif qu'une pneumonie virale, de comparer la prévalence d'infection pulmonaire bactérienne précoce et l'incidence d'IAVM entre les patients de la 1ère et 2nde vagues pandémiques de COVID-19, de déterminer l'impact de la PAVM sur la mortalité des patients atteints de COVID-19, de déterminer l'impact de la corticothérapie sur l'incidence des PAVM chez les patients atteints de COVID-19, et de comparer l'incidence d'API chez les patients admis pour COVID-19 ou grippe.Méthodes : Cohorte multicentrique européenne observationnelle rétrospective impliquant 36 services de réanimation, incluant consécutivement des patients adultes sous VM pendant plus de 48h, répartis en quatre groupes selon leur motif d'admission: COVID-19 (1ère et 2nde vagues), grippe, et autres.Résultats : Au total, 2172 patients ont été inclus. La prévalence d'infection pulmonaire bactérienne dans les 48 heures suivant l'intubation était significativement inférieure chez les patients COVID-19 (9,7%) par rapport à ceux admis pour grippe (33,6% ; odds ratio (OR) ajusté 0,23 ; intervalle de confiance à 95% 0,16-0,33). L'incidence des IAVM était significativement plus élevée chez les patients COVID-19 (50,5%) comparée à ceux admis pour grippe (30,3% ; sub hazard ratio (sHR) ajusté 1,6 (1,26-2,04)) et sans infection virale (25,3% ; sHR ajusté 1,7 (1,20-2,39)), avec une incidence de PAVM significativement plus élevée dans le groupe COVID-19 par rapport aux deux autres groupes. La prévalence d'infection précoce a significativement augmenté entre la 1ère et la 2nde vague (9,7 vs 14,9%, OR ajusté 1,52 (1,04-2,22)), tout comme l'incidence des PAVM (36 vs 44,8% ; sHR ajusté 1,37 (1,12-1,66). La PAVM était associée à une augmentation significative de la mortalité à J28 chez les patients COVID-19 (HR ajusté 1,65 (1,11-2,46)), ce qui n'était pas observé chez les patients admis pour grippe et sans infection virale. Cependant, aucune différence significative dans l'hétérogénéité de l'association entre PAVM et mortalité n'était constatée entre les trois groupes de l'étude. La relation entre la corticothérapie et l'incidence de PAVM n'était pas statistiquement significative (p=0,082 pour l'effet global), avec un risque de PAVM variant au cours du temps à partir de l'initiation du traitement. Enfin, l'incidence d'API putative (définie par l'algorithme AspICU) était significativement plus faible dans le groupe COVID-19 par rapport au groupe grippe (2,5% vs 6% ; HR cause-spécifique ajusté 3,29 (1,53-7,02). Conclusion : Le projet CoVAPid a mis en évidence une prévalence moindre d'infections pulmonaires bactériennes précoces chez les patients COVID-19 par rapport à ceux atteints de grippe, avec une augmentation significative entre la 1ère et la 2nde vague pandémique. L'incidence de PAVM était plus élevée chez les patients COVID-19, comparativement aux patients admis pour grippe ou sans infection virale à l'admission, et augmentait significativement entre la 1ère et la 2nde vague. Chez les patients COVID-19, la corticothérapie n'avait pas d'effet notable sur l'incidence des PAVM, et la survenue d'une PAVM était associée à une augmentation significative de la mortalité à J28. L'incidence d'API était plus faible au cours de la COVID-19, en comparaison à la grippe<br>Objectives: The CoVAPid project aimed to study the impact of SARS-CoV-2 infection on the epidemiology of bacterial and fungal respiratory infections in critically ill patients requiring mechanical ventilation (MV). Three entities were analyzed: early bacterial pulmonary infections, bacterial ventilator-associated lower respiratory tract infections (VA-LRTI) including ventilator-associated pneumonia (VAP) and ventilator-associated tracheobronchitis (VAT), and invasive pulmonary aspergillosis (IPA). The main objectives were to compare the prevalence of early bacterial pulmonary infection between patients admitted for COVID-19 and influenza, to compare the incidence of VA-LRTI among patients admitted for COVID-19, influenza, or other reasons than viral pneumonia, to compare the prevalence of early bacterial pulmonary infection and the incidence of VA-LRTI between patients from the 1st and 2nd pandemic waves of COVID-19, to determine the impact of VAP on mortality in patients with COVID-19, to assess the effect of corticosteroid therapy on the incidence of VAP in patients with COVID-19, and to compare the incidence of IPA between patients with COVID-19 and influenza. Methods: This was a retrospective observational multicenter European cohort involving 36 centers. Adult patients under MV for more than 48 hours were consecutively included and divided into four groups according to their ICU admission cause: COVID-19 (1st and 2nd wave, influenza, and others. Results: A total of 2172 patients were included. The prevalence of bacterial pulmonary infections within 48 hours following intubation was significantly lower in COVID-19 patients (9.7%) compared to those admitted for influenza (33.6%, adjusted odds ratio (OR) 0.23, 95% confidence interval 0.16-0.33). The incidence of VA-LRTI was significantly higher in COVID-19 patients (50.5%) compared to those admitted for influenza (30.3%, adjusted sub-hazard ratio (sHR) 1.6 (1.26-2.04)) and those without viral infection (25.3%, sHR 1.7 (1.20-2.39)), with a significantly higher incidence of VAP in the COVID-19 group compared to the other two groups. The prevalence of early infection significantly increased between the 1st and 2nd wave (9.7 vs 14.9%, adjusted OR 1.52 (1.04-2.22)), as did the incidence of VAP (36 vs 44.8%; adjusted sHR 1.37 (1.12-1.66)). VAP was associated with a significant increase in 28-day mortality in COVID-19 patients (adjusted HR of 1.65 (1.11-2.46)), which was not observed in patients admitted for influenza and without viral infection. However, no significant difference in the heterogeneity of the association between VAP and mortality was observed among the three study groups. The relationship between corticosteroid exposure and the incidence of VAP was not statistically significant (p=0.082 for the overall effect), despite a varying risk of VAP over time since the initiation of treatment. Finally, the incidence of putative IPA (defined by the AspICU algorithm) was significantly lower in the COVID-19 group compared to the influenza group (2.5% vs 6%, cause-specific adjusted HR 3.29 (1.53-7.02)). Conclusion: The CoVAPid project highlighted a lower prevalence of early bacterial pulmonary infections in COVID-19 patients compared to those with influenza, with a significant increase between the 1st and 2nd pandemic wave. The incidence of VAP was higher in COVID-19 patients, compared to patients admitted for influenza or without viral infection at admission, and significantly increased between the 1st and 2nd wave. In COVID-19 patients, corticosteroid therapy had no significant effect on the incidence of VAP, and the occurrence of VAP was associated with a significant increase in 28-day mortality. The incidence of IPA was lower among patients with COVID-19 than those with influenza

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "COVID-19 – complications"

1

Mallick, Umair. Cardiovascular Complications of COVID-19. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-90065-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Banach, Maciej, ed. Cardiovascular Complications of COVID-19. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-15478-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mohan, Anant, and Saurabh Mittal, eds. Post COVID-19 Complications and Management. Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-4407-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

C, Kelsey. CF-EF: Complications. Kelsey C., 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Sobti, R. C., Naranjan S. Dhalla, Masatoshi Watanabe, and Aastha Sobti, eds. Delineating Health and Health System: Mechanistic Insights into Covid 19 Complications. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-5105-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mohan, Anant, and Saurabh Mittal. Post COVID-19 Complications and Management. Springer, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Post COVID-19 Complications and Management. Springer, 2023.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mallick, Umair. Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes. Springer International Publishing AG, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Priori, Alberto, ed. Neurology of COVID-19. Milano University Press, 2021. http://dx.doi.org/10.54103/milanoup.57.

Full text

Abstract:

The authors will present a comprehensive account of the neurological aspects of SARS-CoV-2 infection. The aim is to provide a practical clinical book which will serve as a guide for clinicians from all specialties involved in the management of COVID-19 patients. The authors share the extensive clinical experience gained in major hospitals in Lombardy, the first European region to face the COVID-19 emergency in 2020. All are recognized international experts in their respective fields and have been involved in the management of COVID-19 cases from the very beginning of the Italian SARS-CoV-2 outbreak. The text begins with a description of pathobiological and pathophysiological aspects related to the involvement of the nervous system, moving on to the discussion of the neurological complications observed in COVID-19 patients; these range from central to peripheral symptoms, and can occur in the acute or post-acute phases of the disease. Further topics are: neuropathology, seizures and EEG, neuroimaging, delirium, encephalomyelitis, stroke, psychopathology and psychiatry, neuropsychology and cognitive impairment, neuromuscu-lar disorders, and the impact of COVID-19 on other pre-existing neurological disorders. In addi-tion, the book will discuss the new developments in teleneurology approaches, which have been a direct response to the ongoing pandemic. Finally, the possible neurological complications of the COVID-19 vaccines and the neurological complications in children will be considered.Each chapter will present a critical review of the existing literature concerning the specific subject matter, followed by practical clinical recommendations, as well as personal considerations based on the experience gained by each author during the course of the COVID-19 pandemic. Neurology of COVID-19 will be an original and innovative reference book for clinicians of all the specialties involved in the management of patients with SARS-CoV-2 infection

APA, Harvard, Vancouver, ISO, and other styles

10

Cardiovascular Complications of COVID-19: Acute and Long-Term Impacts. Springer International Publishing AG, 2024.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "COVID-19 – complications"

1

Walton, Dean, Roberto Acampora, Greta Karen Wood, et al. "Neurological Complications of COVID-19." In Frontiers of COVID-19. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08045-6_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Moorjani, Harish, and S. K. Gupta. "COVID-19: An Overview." In Post COVID-19 Complications and Management. Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-4407-9_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Saxena, Rohit, and Rebika Dhiman. "Eye Complications Following COVID-19." In Post COVID-19 Complications and Management. Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-4407-9_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Roy, Ambuj, and Aseem Basha M. "Cardiovascular Complications Following COVID-19." In Post COVID-19 Complications and Management. Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-4407-9_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Goswami, Rudra Prosad, and Uma Kumar. "Rheumatological Complications Following COVID-19." In Post COVID-19 Complications and Management. Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-4407-9_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Egloff, Charles, and Olivier Picone. "Complications of COVID-19 in Pregnant Women." In COVID-19 and Perinatology. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-29136-4_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tavares, Cristiane, Rachel Emy Straus Takahashi, and Carlos Viana Poyares Jardim. "Complications of Corona Virus Disease." In Clinical Synopsis of COVID-19. Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-8681-1_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Mallick, Umair. "Thrombosis in CoViD19." In Cardiovascular Complications of COVID-19. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-90065-6_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Mallick, Umair. "The Pathological Features of CoViD19 Cardiovascular Complications." In Cardiovascular Complications of COVID-19. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-90065-6_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mallick, Umair. "Treatment Options in CoViD19." In Cardiovascular Complications of COVID-19. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-90065-6_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "COVID-19 – complications"

1

Heydari, G. "COVID-19 and smoking: Worst complications and outcome." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sharma, V., J. Bahk, B. Dolan, M. Sehmbhi, J. Y. Fung, and Y. I. Lee. "Complications of Tracheostomies in the COVID-19 Era." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Zhao, Ruobing. "Cardiovascular complications and long-haulers of COVID-19." In International Conference on Modern Medicine and Global Health (ICMMGH 2023), edited by Sheiladevi Sukumaran. SPIE, 2023. http://dx.doi.org/10.1117/12.2692344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Disserol, Caio, Alessandra Filpo, Taís Luise Denicol, et al. "Thromboembolic Central Nervous System Complications of COVID-19." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.492.

Full text

Abstract:

Context: COVID-19 is well-known to increase the risk of developing thromboembolism; thus, patients may present with diverse neurovascular manifestations. Case report: A 56-year-old man presented with sudden onset of incoordination of his left arm and leg. He also had a history of recurrent episodes of transient left hemithoracic pain radiating to his left arm, along with right visual hemi-field positive phenomena. Additionally, he reported self-limited fever and anosmia three weeks earlier. Examination revealed left hemiataxia (NIHSS score: 2). Initial assessment with brain CT, intracranial and cervical CT angiography was normal. Shortly after admission, the patient developed acute weakness of his four limbs and urinary retention. Neurological exam showed left homonimous hemianopia, asymmetric tetraparesis and a superficial sensory level at C4. Neuraxis MRI was performed and diffusion-weighted imaging revealed acute ischemic lesions in the occiptal lobes, cerebellum and cervicalthoracic spine. A thorough diagnostic work-up was conducted. Laboratory tests were unremarkable, including inflammatory markers, viral hepatitis, HIV and syphilis serologies, as well as rheumatologic tests and a thrombophilia panel, except for SARS-COV-2 serology, with detection of IgM antibodies. RT-PCR nasopharyngeal swab was negative. Further investigation with CSF analysis, CT angiography of the aorta, transthoracic echocardiogram, 24-hour holter monitoring and transcranial Doppler didn’t show any abnormalities. Transesophageal echocardiogram revelead a minor patent foramen ovale. Conclusion: This is a case of acute cerebral, cerebellar and spinal embolic infarction, probably related to Covid-19, illustrating the infection’s associated coagulopathy¹.

APA, Harvard, Vancouver, ISO, and other styles

5

Martínez Menéndez, Joaquin, Alberto Alonso Fernández, Carla Suárez Castillejo, et al. "Cardiopulmonary complications after pulmonary thrombosis (PT) in COVID-19." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa2251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

MATTOS, ARTHUR FIOROTTO DE, NATHALIA SILVEIRA BARSOTTI, and RAFAEL RIBEIRO ALMEIDA. "RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS AND COVID-19 COMPLICATIONS." In II Brazilian Congress of Health. HEALTH2021, 2021. http://dx.doi.org/10.51162/health2021-0001.

Full text

Abstract:

The world faces today a pandemic of unquestionable importance, caused by an infection with a new enveloped RNA virus that belongs to the Coronaviridae family. The new coronavirus (SARS-CoV 2) uses a glycoprotein present on its surface to bind to and infect host cells that express the angiotensin converting enzyme II (ACE-2). Although different tissues may be targeted by the virus, respiratory complications remain as the main cause of death. It has been demonstrated that Renin-Angiotensin-Aldosterone System (RAAS) inhibitors increase ACE-2 expression in animal models, raising the concern that patients under treatment with these drugs could become more susceptible to COVID-19 complications. Here, we discuss the impact of RAAS inhibitors on COVID-19 outcomes and show that no evidence so far supports that the use of these drugs could pose a risk to SARS-CoV 2-infected patients. In fact, clinical data suggest that RAAS inhibitors may even act in a protective way against COVID-19 complications and should not be discontinued.,

APA, Harvard, Vancouver, ISO, and other styles

7

Islam Tamim, Syed Mominin, MD Nadim Hasan, Md Tafsimul Islam Tanzid, and Tanvir Ahmed. "Post Covid-19 Complications Detection Using ML Review Paper." In 6th Industrial Engineering and Operations Management Bangladesh Conference. IEOM Society International, 2023. http://dx.doi.org/10.46254/ba06.20230151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Martins, Bruna de Almeida, Fernanda Oliveira Carrijo, Guilherme Brandão Martins, Lívia Barbosa Santos, and Erla Lino Ferreira de Carvalho. "Implication of COVID-19 in Guillain-Barre Syndrome: a systematic review." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.095.

Full text

Abstract:

Introduction: The SARS-CoV-2 virus, responsible for COVID-19, was declared in 2020 as a pandemic by the WHO. Due to the new scientific discoveries, correlations between SARS- CoV-2 and neurological manifestations were established. Among them, the Guillain-Barre Syndrome (GBS) is a concern, since it culminates in patient debility. The study has the relevance of knowing the impacts and complications of COVID 19 associated with GBS. In this context, the study presents the guiding question: What are the complications of Covid 19 with GBS? Objectives: To review the literature, highlighting the relationship between COVID- 19 and neurological complications, mainly GBS. Methodology: The study is a literature review, using the PubMed database. The descriptors “Guillain Barre” and “Covid 19” and “Complications” from the last year were used and 56 articles (free, of the type Books and documents; Clinical trial; Controlled and randomized testing; and Analysis) were selected. Results: The studies have shown the existence of an association between GBS and SARS-CoV-2. GBS associated with Covid-19 resulted in manifestations such as facial weakness, limb paresthesia, pain and weakness in the extremities with areflexia. The onset time of neurological symptoms was 6.5 to 11 days after respiratory or systemic characteristics. The liquor is normocellular, hyperproteinorchy, absence of anti-ganglioside antibodies and no SARS-CoV2 was detected in the sample, showing that there is no direct root infection or viral replication. Conclusion: It is concluded that there are neurological complications associated with COVID- 19, emphasizing the GBS, which highlights the need for measures of initial interventions.

APA, Harvard, Vancouver, ISO, and other styles

9

Anwar, A., N. Ramos-Bascon, A. A. Crerar-Gilbert, N. Barnes, and B. Madden. "Large Airway Complications in Severely Ill Patients with COVID 19." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1755.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Patel, K. D., D. Morris, and A. Iardino. "Post-Covid-19 Complications: Hemoptysis in a Middle-Aged Man." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "COVID-19 – complications"

1

Wiemers, Emily, Scott Abrahams, Marwa AlFakhri, V. Joseph Hotz, Robert Schoeni, and Judith Seltzer. Disparities in Vulnerability to Severe Complications from COVID-19 in the United States. National Bureau of Economic Research, 2020. http://dx.doi.org/10.3386/w27294.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Viksna, Ludmila, Oksana Kolesova, Aleksandrs Kolesovs, Ieva Vanaga, and Seda Arutjunana. Clinical characteristics of COVID-19 patients (Latvia, Spring 2020). Rīga Stradiņš University, 2020. http://dx.doi.org/10.25143/fk2/hnmlhh.

Full text

Abstract:

Data include following variables: Demographics, epidemiological history, comorbidities, diagnosis, complications, and symptoms on admission to the hospital. Also, body’s temperature and SpO2. Blood cells: white cells count (WBC), neutrophils (Neu), lymphocytes (Ly), eosinophils (Eo) and monocytes (Mo), percentages of segmented and banded neutrophils, erythrocytes (RBC), platelet count (PLT), hemoglobin (Hb), and hematocrit (HCT); Inflammatory indicators: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); Tissue damage indicators: alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and troponin T (TnT); Electrolytes: potassium and sodium concentration; Renal function indicators: creatinine and glomerular filtration rate (GFR); Coagulation tests: D-dimer, prothrombin time, and prothrombin index on admission to the hospital.

APA, Harvard, Vancouver, ISO, and other styles

3

Chauvin, Juan Pablo, Annabelle Fowler, and Nicolás Herrera L. The Younger Age Profile of COVID-19 Deaths in Developing Countries. Inter-American Development Bank, 2020. http://dx.doi.org/10.18235/0002879.

Full text

Abstract:

This paper examines why a larger share of COVID-19 deaths occurs among young and middle-aged adults in developing countries than in high-income countries. Using novel data at the country, city, and patient levels, we investigate the drivers of this gap in terms of the key components of the standard Susceptible-Infected-Recovered framework. We obtain three main results. First, we show that the COVID-19 mortality age gap is not explained by younger susceptible populations in developing countries. Second, we provide indirect evidence that higher infection rates play a role, showing that variables linked to faster COVID-19 spread such as residential crowding and labor informality are correlated with younger mortality age profiles across cities. Third, we show that lower recovery rates in developing countries account for nearly all of the higher death shares among young adults, and for almost half of the higher death shares among middle-aged adults. Our evidence suggests that lower recovery rates in developing countries are driven by a higher prevalence of preexisting conditions that have been linked to more severe COVID-19 complications, and by more limited access to hospitals and intensive care units in some countries.

APA, Harvard, Vancouver, ISO, and other styles

4

Hashemi, Sara, Hengameh Ferdosian, and Hadi Zamanian. Accuracy of artificial intelligence in CT interpretation in covid-19: a systematic review protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.10.0048.

Full text

Abstract:

Review question / Objective: The aim of this systematic review is to compare the accuracy of artificial intelligence algorithms with radiologist panels in CT interpretation in covid-19. Condition being studied: COVID-19 disease was reported as the cause of the outbreak of pneumonia at the end of 2019. One of the main complications of COVID-19 is pulmonary involvement which could be diagnosed by CT-scan dominantly. Because of the increasing rate of these patients along with considering patients in remote areas, CT interpretations are a heavy burden on radiologists. Therefore artificial intelligence algorithms have become critical and time-saving systems in decision-making for these patients.

APA, Harvard, Vancouver, ISO, and other styles

5

Seme, Assefa, Solomon Shiferaw, Ayanaw Amogne, et al. Impact of the COVID-19 Pandemic on Adolescent Sexual and Reproductive Health in Ethiopia. Guttmacher Institute, 2021. http://dx.doi.org/10.1363/2021.33198.

Full text

Abstract:

Key Points The COVID-19 pandemic and its associated restrictions raised concerns that adolescents in Ethiopia may face reduced access to youth-friendly sexual and reproductive health services. Public and private service statistics data reveal that from March through the end of 2020, the COVID-19 pandemic had at least a short-term impact on adolescent sexual and reproductive health outcomes. The COVID-19 pandemic is estimated to have resulted in an annualized increase of: 20,738 adolescents with an unmet need for contraception 8,884 unintended pregnancies among adolescents Approximately 10.1 million Ethiopian birr (more than US$250,000) in costs for the Ethiopian health system for pregnancy-related and newborn care 438 adolescent women with major obstetric complications 14 adolescent maternal deaths Ethiopia’s Ministry of Health and private health providers could take several steps to ensure that access to sexual and reproductive health services for adolescents continues throughout the remainder of the COVID-19 pandemic: Adopt an emergency response plan that addresses adolescents’ sexual and reproductive health needs Support health care workers, particularly health extension workers, to increase access to contraceptives for adolescents Engage adolescents at all levels of the Ministry of Health decision-making process Support the expansion of youth-friendly services across regions with additional staff and resources

APA, Harvard, Vancouver, ISO, and other styles

6

Ding, Yukang, Xixia Chen, and Yongpeng Ge. Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.9.0084.

Full text

Abstract:

Review question / Objective: Reports of unexpected side effects have accompanied the vaccination of larger proportions of the population against coronavirus disease 2019 (COVID-19), including a few cases of inflammatory myopathy (IM). In a bid to improve understanding of the clinical course of vaccine complications, a systematic review of reported cases of IM following COVID-19 vaccination has been conducted. Condition being studied: Safety concerns have surrounded the vaccines since their development, with common adverse effects including local reaction at the site of injection and diverse non-specific flu-like symptoms (9). Most symptoms occur soon after vaccination and resolve within a short period but some serious events such as myopericarditis and cerebral venous thrombosis post COVID-19 vaccination had been reported. Meanwhile, some rare cases of vaccine-associated IMs have been reported. The current study systematically reviewed IM cases reported post-COVID-19 vaccination to date. Clinical and laboratory features are described and therapy and prognosis discussed.

APA, Harvard, Vancouver, ISO, and other styles

7

Grace, Dr Golla Reethi Shiny, Dr Anu K., Dr Pratyusha Choudary G., and Dr M. v. PATTERN OF THE HEMATOLOGICAL PARAMETERS IN COVID-19 PATIENTS. World Wide Journals, 2023. http://dx.doi.org/10.36106/ijar/5106302.

Full text

Abstract:

Background: The coronavirus (SARS CoV 2)-related viral disease COVID 19 causes acute respiratory disease with severe symptoms. Numerous biomarkers of infection and inammation have been found to inuence the severity of disease. Acute respiratory infection, fever, pneumonia, cough, tiredness, and inammation are frequent clinical ndings during hospitalisation. The severity of the disease and a possibility of disease progression can be determined by circulating biomarkers like TWBC count, NLR and CRP that reect inammation. This is a retrospective study conducted on eight Material and Methods: y COVID-19 positive patients admitted at Dr.Pinnamaneni Siddhartha Institute of Medical Sciences & RF, ChinnaAvutapally from 1st January 2021 to 30th June 2021. Results: Among the 80 COVID 19 patients studied, there are 63% males and 37% females. 46% of patients showed leucocytosis, 43% showed increased NLR and 60 % showed raised CRP. Hematological parameters in COVID 19 are important for di Conclusion: agnosis, complication management, prognosis, and patient recovery. These parameters must be effectively integrated into clinical algorithms and therapeutic decision making in addition to clinical assessment

APA, Harvard, Vancouver, ISO, and other styles

8

One in two people hospitalised with COVID-19 develop complications and may need support. National Institute for Health Research, 2022. http://dx.doi.org/10.3310/alert_48926.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Brain and nerve complications are more common than expected in younger patients with severe COVID-19. National Institute for Health Research, 2020. http://dx.doi.org/10.3310/alert_41964.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!